NCT01287091View on ClinicalTrials.gov

A 3-Part Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0980, the Effect of Food, and the Effect of Rabeprazole on the Pharmacokinetics of the Tablet

PHASE1CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

October 14, 2010

Primary Completion Date

February 3, 2011

Study Completion Date

February 3, 2011

Conditions
Healthy Volunteer
Interventions
DRUG

GDC-0980

Oral tablet dose

DRUG

GDC-0980

Oral capsule dose

DRUG

GDC-0980

Oral tablet dose in fed state

DRUG

GDC-0980

Oral repeating dose in fasting state

DRUG

GDC-0980

Oral repeating dose in fed state

DRUG

GDC-0980

Oral tablet in a fasting state

DRUG

rabeprazole

Oral repeating dose

Trial Locations (1)

78744

Investigational Site, Austin

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY